I've responded in several threads recently - Prato's and I believe at least one other asking for experience with Firmagon. In one of those threads I was asked why I was on Firmagon rather than Lupron and I replied that I was in the control group of a clinical trial and that is what the control arm called for. Also several posters have commented on having been on both Firmagon and Lupron at different times.
This morning my wife forwarded me an update on a friend of hers who is being treated for multple myeloma. He commented about
his period of Progression Free Survival (PFS), which prompted me to do a search for PFS relative to prostate cancer, which in turn led to the paper I link below. It discusses PFS of patients treated with Firmagon (a GnRH antagonist) vs patients treated with an LHRH agonist such as Lupron.
The paper concludes:
"Conclusions: Improved PSA-PFS was shown in pts treated with degarelix vs LHRH agonists in metastatic or high risk PCa pts irrespective of region. These results suggest delay of disease progression with initial use of a GnRH antagonist as compared with LHRH agonists across global regions."
This doesn't necessarily mean that improved Progression Free Survival will also lead to improved Overall Survival. But it is another very useful piece of information for me and I assume others here to ponder when choosing courses of treatment.
As I've mentioned elsewhere I've thus far had no SEs from Firmagon, and given the conclusions of this paper, I'm inclined to stay on Firmagon even though it means monthly rather than quarterly or longer intervals between shots./academic.oup.com/annonc/article/27/suppl_6/735P/2799473
Post Edited (Bohemond) : 8/22/2018 9:03:49 AM (GMT-6)